Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.42 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252546 | 1.00 | RORC (0.43) | RORCKDM4EPDE4BNAMPTNR1H2 | |
| SCHEMBL570438 | 0.85 | RORC (0.45) | RORCKDM4EPDE4BNAMPTNR1H2 | |
| SCHEMBL12988240 | 0.81 | NR1H2 (0.43) | RORCPDE4BNAMPTNR1H2 | |
| SCHEMBL12988243 | 0.81 | NR1H2 (0.43) | RORCPDE4BNAMPTNR1H2 | |
| SCHEMBL23091747 | 0.80 | NAMPT (0.51) | RORCKDM4EPDE4BNAMPTNR1H2 | |
| SCHEMBL17736163 | 0.80 | GPR119 (0.53) | RORCKDM4EPDE4BNAMPTNR1H2 | |
| SCHEMBL20607546 | 0.80 | RORC (0.48) | RORCKDM4EPDE4BNAMPTNR1H2 | |
| SCHEMBL1994292 | 0.80 | USP2 (0.40) | RORCKDM4EPDE4BNAMPTGPR119 | |
| SCHEMBL1994287 | 0.80 | USP2 (0.40) | RORCKDM4EPDE4BNAMPTGPR119 | |
| SCHEMBL29538452 | 0.80 | USP2 (0.40) | RORCKDM4EPDE4BNAMPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2601190-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | AH USA 42 LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | RORC 519/4885KDM4E 2316/4885PDE4B 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.